In Vivo PET Imaging of CD20 Using Cu-64-labeled F(ab)2 Fragment of Obinumumab in Lymphoma Models

Lei Kang,Dawei Jiang,Weijun Wei,Dalong Ni,Carolina Ferreira,Jonathan Engle,Rongfu Wang,Weibo Cai

2018-01-01

Journal of Nuclear Medicine

Abstract:1123 Objectives: Non-Hodgkin lymphoma (NHL) is the tenth most common cancer worldwide. CD20 over-expressed B-cell NHL usually shows progressive malignancy. Obinutuzumab (Gazyva) is an FDA-proved fully humanized monoclonal antibody (mAb) that targets CD20 on mature B cells. In our previous study, 89Zr-Df-obinutuzumab exhibited sensitivity and specificity for CD20 targeting in vivo using PET imaging. However, long blood circulation of intact mAb usually increases the radioactive exposure and background signal. MAb F(ab’)2 fragments can be taken up by tumors but rapidly eliminated from the blood and most normal tissues so that provide high tumor-to-background ratios. In this study, F(ab’)2 fragment of obinutuzumab was produced and labeled for immunoPET imaging of CD20 in lymphoma. Methods: F(ab’)2 fragment of obinutuzumab was produced using IdeS enzyme and further purified with Protein A beads, which were provided by Promega Corp. Human non-specific IgG F(ab’)2 fragment was also produced for the control group. After obinutuzumab-F(ab’)2 was evaluated using HPLC and gel electrophoresis, it was conjugated with p-SCN-Bn-NOTA (NOTA), then radiolabeled with 64Cu (t1/2 = 12.7 h). Obinutuzumab-F(ab’)2 was labeled with Fluorescein dye (Thermo Fisher) for flow cytometry and confocal assays in vitro. CD20-positive Ramos lymphoma cells were subcutaneously implanted to build tumor-bearing model. Serial PET imaging and biodistribution studies were performed after injection of 64Cu-NOTA-obinutuzumab- F(ab’)2 or 64Cu-NOTA-IgG-F(ab’)2 in Ramos lymphoma model. Finally, histological analysis was performed to verify the distribution of obinutuzumab-F(ab’)2 in the tumor, as well as CD20 expression. Results: Obinutuzumab-F(ab’)2 of high purity was produced by IdeS digestion system of obinutuzumab, which was confirmed by SDS-PAGE and HPLC analysis. 64Cu-NOTA-obinutuzumab-F(ab’)2 was achieved with high labeling yields more than 90%. PET imaging revealed rapid and persistent tumor uptake of 64Cu-NOTA-obinutuzumab-F(ab’)2 in Ramos model (4.3 ± 1.8, 7.5 ± 1.8, 7.1 ± 1.1, 6.8 ± 1.0, and 5.45 ± 0.5 %ID/g at 10 min, 4, 16, 24, and 48 h post-injection respectively, n = 4). It showed high tumor-to-background ratios at 48 h post-injection (tumor-to-blood ratio = 5.6 ± 1.5; tumor-to-muscle ratio = 22.8 ± 8.4). Additionally, 64Cu-NOTA-IgG-F(ab’)2 demonstrated a near-background tumor uptake in Ramos model, with the highest tumor uptake of only 1.9 ± 0.3 %ID/g at 12 h post-injection. Biodistribution studies verified these imaging results. Immunofluorescent staining of tumor tissues displayed strong CD20 expression in the tumor of Ramos. Conclusion: This study showed 64Cu-NOTA-obinutuzumab-F(ab’)2 showed rapid and persistent tumor uptake in CD20-positive lymphoma with low background, which may allow for a short-term immunoPET imaging in the future clinical application.